URL has been copied successfully!
U.S. stock futures were lower this morning, with the Dow futures falling around 400 points on Thursday.
Shares of Alto Neuroscience Inc (NYSE:ANRO) fell sharply in pre-market trading after the company announced topline data from its Phase 2 proof-of-concept clinical trial evaluating ALTO-101 did not achieve statistical significant on primary electroencephalography or cognitive endpoints versus placebo.
Alto Neuroscience shares dipped 13.6% to $20.16 in pre-market trading.
Here are some other stocks moving lower in pre-market trading.
- Akso Health Group – ADR (NASDAQ:AHG) fell 9.4% to $2.10 in pre-market …
Please follow us:
This post was originally published here
